Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00188084|
Recruitment Status : Unknown
Verified September 2005 by University Hospital, Angers.
Recruitment status was: Recruiting
First Posted : September 16, 2005
Last Update Posted : October 28, 2005
Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:
- A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
- The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.
The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival.
Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.
|Condition or disease||Intervention/treatment|
|Adult Acute Lymphoblastic Leukemia||Procedure: DNA Index Procedure: S-Phase% Procedure: CD45 expression Procedure: P16 metabolic way|
|Study Type :||Observational|
|Enrollment :||400 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Official Title:||Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial|
|Study Start Date :||November 2003|
|Study Completion Date :||September 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00188084
|Contact: Agnès F CHASSEVENT, PhD||33-(0)email@example.com|
|CRLCC Centre Paul Papin||Recruiting|
|Angers, France, 49933|
|Contact: Agnès F CHASSEVENT, PhD 33-(0)2-41-35-27-00 firstname.lastname@example.org|
|Sub-Investigator: Mathilde HUNAULT-BERGER, MD,PhD|
|Sub-Investigator: Martine FFrench, MD,PhD|
|Sub-Investigator: Marina Lafage-Pochitaloff, MD,PhD|
|Sub-Investigator: Françoise HUGUET, MD|
|Principal Investigator:||Laurence M Baranger, MD||University Hospital, Angers|